This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lincoff, A. M. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Lincoff, A. M. Articles by Topol, E. J. Related Collections Platelet function inhibitors Catheter-based coronary and valvular interventions: other Platelets

(Circulation. 2000;102:2923.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization

Results From the EPILOG Randomized Trial

A. Michael Lincoff, MD; Daniel B. Mark, MD, MPH; James E. Tcheng, MD; Robert M. Califf, MD; Mohan V. Bala, PhD; Keaven M. Anderson, PhD; Linda Davidson-Ray, BA; J. David Knight, MS; Catherine F. Cabot, MD; Eric J. Topol, MD; for the EPILOG Investigators¹

From the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (A.M.L., E.J.T.); Duke Clinical Research Institute, Durham, NC (D.B.M., J.E.T., R.M.C., L.D.R., J.D.R.); and Centocor, Malvern, Pa (M.V.B., K.M.A., C.F.C.).

Correspondence to A. Michael Lincoff, MD, Associate Professor of Medicine, Department of Cardiology, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195.

Background—In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30 days by 56% among patients undergoing percutaneous coronary revascularization, without increased bleeding complications.

Methods and Results—A prospective economic assessment was performed in the 2792 patients enrolled in EPILOG. Patients were randomized to receive placebo with standard-dose weight-adjusted heparin, abciximab with low-dose weight-adjusted heparin, or abciximab with standard-dose weight-adjusted heparin during percutaneous coronary intervention. Hospital billing data for the baseline hospitalization were collected for 2581 patients (92.4% of total) and imputed for the remainder, with physician fees estimated from the Medicare Fee Schedule. For the baseline hospitalization, medical costs (hospitalization and physician fees) averaged $9632 for the placebo arm compared with $8758 (P=0.005) and $9092 (P=0.176) for the abciximab with low-dose and standard-dose heparin arms, respectively. Inclusive of average drug cost ($1454 to $1457), the net incremental baseline cost of these 2 abciximab strategies was $583 with low-dose weight-adjusted heparin and $914 with standard-dose weight-adjusted heparin. During 6-month follow-up, average hospital costs were not significantly different in the 3 treatment groups; cumulative net incremental costs were $1236 and $1268 in the abciximab with low-dose and standard-dose heparin groups, respectively.

Conclusions—Treatment with abciximab and low-dose, weight-adjusted heparin during percutaneous coronary revascularization reduces ischemic events and associated costs, thereby offsetting some of the cost of the drug. The suppression of bleeding complications associated with this agent by heparin dose reduction optimizes the economic attractiveness of this treatment strategy.

This article has been cited by other articles:

				G. Tanzilli, M. Sordi, A. Arrivi, E. Mangieri, and M. Scappaticci Acute profound abciximab induced thrombocytopenia: a correct management of a methodological error BMJ Case Reports, October 5, 2009; 2009(oct05_1): bcr1220081381 - bcr1220081381. [Abstract] [Full Text]

				R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537. [Abstract] [Full Text] [PDF]

				J. Machecourt, E. Bonnefoy, G. Vanzetto, P. Motreff, S. Marliere, A. Leizorovicz, B. Allenet, J. M. Lacroute, J. Cassagnes, and P. Touboul Primary angioplasty is cost-minimizing compared with pre-hospital thrombolysis for patients within 60 min of a percutaneous coronary intervention center: The Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) cost-efficacy sub-study J. Am. Coll. Cardiol., February 15, 2005; 45(4): 515 - 524. [Abstract] [Full Text] [PDF]

				P. A. Cowper, K. Udayakumar, M. H. Sketch Jr, and E. D. Peterson Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention J. Am. Coll. Cardiol., February 1, 2005; 45(3): 369 - 376. [Abstract] [Full Text] [PDF]

				D. J. Cohen, A. M. Lincoff, T. A. Lavelle, H.-L. Chen, A. Bakhai, R. H. Berezin, D. Jackman, I. J. Sarembock, and E. J. Topol Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1792 - 1800. [Abstract] [Full Text] [PDF]

				S N Makoni Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature Heart, December 1, 2001; 86(6): e18 - 18. [Abstract] [Full Text] [PDF]